It is estimated that over 100 million Americans suffer from chronic pain at an annual cost to our society of over 500 billion dollars. For centuries, opioid drugs such as morphine have been the first-line treatment for severe pain. However, over time tolerance to opioid analgesia develops. Patients face increased risk as well as suffering when opioids lose effectiveness. In this proposal I describe our groundbreaking discovery that the clinically used epidermal growth factor receptor (EGFR;ErbB1) antagonist gefitinib (Iressa) completely reverses morphine tolerance. Based on our findings, we hypothesize that: 1) ErbB signalling is necessary and sufficient to cause morphine tolerance, and functions in series with PDGFR-beta in this process; 2) Chronic opioid administration increases ErbB signalling and may underlie the phenomenon of incomplete cross tolerance; 3) Chronic opioid administration differentially regulates ErbB expression and co-localization in the dorsal root ganglion and substantia gelatinosa; and 4) Opioid-induced ErbB signalling outputs are determined by a tightly regulated transcriptional network. We will test these hypotheses by performing studies with the following Specific Aims: 1) Define and refine the relationship between EGFR/ErbB and PDGFR-beta signalling in the genesis of morphine tolerance; 2) Determine the effects of opioid tolerance on ErbB signalling and whether ErbB signalling can explain incomplete cross tolerance; 3) Define the specific cellular subtypes expressing ErbB receptors in the dorsal root ganglion and dorsal horn of the spinal cord, and determine if their distribution is altered by chronic opioid administration; and 4) Determine the regulation of ErbB signalling responses induced by opioids, and begin to define the network structure that underlies these responses. These studies should dramatically improve our understanding of the molecular mechanisms underlying opioid tolerance. They also may lead to a completely new approach for the treatment of chronic pain. Our findings have the potential to dramatically reduce human suffering and improve the quality of life for untold millions of patients suffering from intractable pain.
Inadequate treatment of chronic pain has afflicted people throughout recorded history. In this application, we describe the groundbreaking discovery of a highly selective and specific substrate of morphine tolerance. We have proposed cutting-edge experiments that will determine whether this finding can be extended to other narcotics and lead to improved treatment and quality of life for the untold millions of patients suffering from intractable pain.
| Puig, Stephanie; Gutstein, Howard B (2017) A ""tail"" of opioid receptor variants. J Clin Invest 127:1221-1224 |
| Puig, Stephanie; Gutstein, Howard B (2017) Opioids: keeping the good, eliminating the bad. Nat Med 23:272-273 |
| Morris, Jeffrey S; Gutstein, Howard B (2016) Detection and Quantification of Protein Spots by Pinnacle. Methods Mol Biol 1384:185-201 |
| Trang, Tuan; Al-Hasani, Ream; Salvemini, Daniela et al. (2015) Pain and Poppies: The Good, the Bad, and the Ugly of Opioid Analgesics. J Neurosci 35:13879-88 |
| Donica, Courtney L; Cui, Yan; Shi, Shanping et al. (2014) Platelet-derived growth factor receptor-? antagonism restores morphine analgesic potency against neuropathic pain. PLoS One 9:e97105 |
